Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Uwe Schuehly
Observed names:
Schuehly, Uwe,
U Schuehly
Institution:
Novartis (Switzerland)
Observed institutions:
Novartis (Switzerland),
Boehringer Ingelheim (Germany),
Novartis Institutes for BioMedical Research
OpenAlex ID:
A5000782031
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials
2018
·
Matteo Lambertini
, Samuel Martel
, et al.
·
Cancer
·
71
PDF
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)
2022
·
Olivier Petricoul
, Arman Nazarian
, et al.
·
Clinical Pharmacokinetics
·
19
Effect of the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide
2018
·
Surya Ayalasomayajula
, Uwe Schuehly
, et al.
·
British Journal of Clinical Pharmacology
·
19
PDF
Evaluation of Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild‐to‐Moderate Hypertension
2017
·
H‐L Hsiao
, TH Langenickel
, et al.
·
Clinical Pharmacology & Therapeutics
·
8
PDF
Safety, tolerability, and pharmacokinetics following multiple oral doses of faropenem daloxate and impact on fecal and oral flora
2000
·
Uwe Schuehly
, Barbara Voith
, et al.
·
Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy
·
3
Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects
2018
·
Uwe Schuehly
, Surya Ayalasomayajula
, et al.
·
European Journal of Clinical Pharmacology
·
2
The Effect of BIBT 986, a Novel Small Molecule Dual Inhibitor of Thrombin and Factor Xa, on Coagulation in a Model of Endotoxin Induced, Tissue Factor Triggered Coagulation Activation in Humans.
2006
·
Bernd Jilma
, Judith M. Leitner
, et al.
·
Blood
·
2
Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
2018
·
Matteo Lambertini
, Samuel Martel
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
9
Citation count:
123
H-index:
4
I10-index:
3
Year
Topic
Type